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Brain-derived factor (BDNF) is a member of neurotrophin family and is localized and upregulated in areas implicated in
epileptogenesis. Several lines of evidence make the BDNF gene a plausible candidate gene for predisposition to epilepsy. In this
study,wetestedthatBDNFmightbeinvolved intheetiologyofchildhoodPE.ToassesswhetherBDNFgeneC270Tpolimorphism
could be implicated in vulnerability to PE, we conducted a case-control association analysis (112 partial epileptic and 100
controls) in Turkish children. Epileptic children were divided into two groups: 1—idiopathic (n = 85) and 2—symptomathic
epilepsy (n = 27). There was no signiﬁcant diﬀerence in genotypic distribution and allelic frequencies of the BDNF gene C270T
polimorphismbetweenthePEandcontrolgroups.However,theBDNFgeneTTgenotypewasmorefrequentlyseenintheepileptic
children (15 versus 11 patients, resp.). Interestingly, in the epilepsy group, both two children with TT genotype have posttraumatic
epilepsy. The data indicate a possible association with the 270T genotype of the BDNF gene with a posttraumatic epilepsy. To
draw any conclusion, further studies using larger sample sizes should be carried out in various ethnic populations in childhood
epilepsies.
1.Introduction
Epilepsy is a condition or a group of conditions involving
transient disturbances in cerebral function caused by abnor-
mal neuronal discharges and characterized by recurrent sei-
zures. Epilepsy is divided into idiopathic, cryptogenic, and
symptomaticforms.Amongthem,idiopathicepilepsymeans
that the primary etiology of epilepsy is believed to be genetic,
and no any underlying pathological disturbance exists [1].
Recentmolecularworkshavesuggestedthatbothgeneralized
and focal idiopathic epilepsy are caused by a genetic defect
[2]. Epilepsy-associated genes largely involve ion channels,
containing voltage- or ligand-gated channels. In addition,
nonion channel genes are also identiﬁed in response to some
epilepsies. Partial epilepsy (PE) has been largely considered
as an environmental-dependent disease in the past; however,
a set of works suggest that PEs also show a genetic factor in
underlying pathogenesis [2].
Brain-derived neurotrophic factor (BDNF), a small
dimeric protein and a member of the neurotrophic factor,
is expressed widely throughout in the developing brain.
Various animal experiments as well as clinical studies have
shown that BDNF regulates neuronal morphology, synap-
togenesis, and neuroprotective eﬀects in diverse areas of the
CNS during development [3]. Several lines of evidence make
the BDNF gene a plausible candidate gene for predisposition
to epilepsy. BDNF regulates neuronal survival, growth, and
connectivity during development and participates in plas-
ticity and maintenance of neurons throughout adulthood
[4]. Increased BDNF levels lead to hyperexcitability both in
vivo and in vitro and exogenous BDNF induces spontaneous
seizures in rats [5, 6]. Furthermore, BDNF is upregulated
by limbic seizures in animal models [7, 8] and in patients
with epilepsy [9, 10]. Variations in the BDNF gene might
alter function and neurotrophic eﬀects of the BDNF protein,
thus ultimately predisposing individuals to the development2 The Scientiﬁc World Journal
of epilepsy. In search of a speciﬁc genetic factor that may
enhance or inhibit posttraumatic development of epilep-
togenesis, Peltola et al. [11] recently suggested a cytokine
gene polymorphism as a possible candidate. Furthermore,
Kanemoto et al. [12]reportedsigniﬁcantcorrelationbetween
the C240T polymorphism in the BDNF gene and PE in
the Japanese population (P = 0.003). As indicated by
Lohoﬀ et al. [13], the C/T polymorphism at position 240
in the noncoding region of the BDNF gene (GenBank
accession number NM001709) corresponds to the 270C/T
polymorphism described by Kunugi et al. [14]. Because the
BDNF C270T nomenclature is much more widely used [15–
20] than C240T, we refer to this polymorphism as C270T.
In our previous study [21], we investigated BDNF serum
concentration in a group of epileptic children and healthy
controls, and we did not ﬁnd a signiﬁcant diﬀerence between
the two groups. On the basis of this experience, we further
tried to evaluate whether BDNF C270T polymorphism is a
useful marker for predicting susceptibility to PEs in children.
2. Patientsand Methods
This study included all outpatients of the Dr. Behc ¸et Uz
Child Disease and Pediatric Surgery Training and Research
Hospital-Pediatric Neurology Polyclinic from 2008 to De-
cember 2010 who gave their informed consent. The patient
group consisted of 112 children, 62.5% males. The control
group (n = 100) comprised unrelated neurologically normal
individuals. Diagnoses were carried out from seizure symp-
tomatology(CommissiononClassiﬁcationandTerminology
of the International League Against Epilepsy, 1989), and
those who showed focal EEG abnormalities or focal lesions
on imaging studies but did not have corresponding seizure
symptoms suggestive of focal origin were excluded. Study
group was divided into two categories: those with PE and
MRI evidence (symptomatic epilepsy) (n = 27), those with
PE essentially normal MRI ﬁndings (idiopathic epilepsy)
(n = 85).
Genomic DNA was extracted from peripheral whole
blood using NucleoSpin Blood kit according to the manufac-
turer’s instructions (Macherey-Nagel, Germany). The C270T
polymorphism of intron 1 of the 5 -UTR sequence was ﬁrst
reported by Kunugi et al. (GenBank accession no. X60202)
[14]. The genotyping procedure consisted of polymerase
chain reaction (PCR) ampliﬁcation and SNP detection of the
C270T variant using the following pair of primers: BDNF-
F: 5 -CAG AGG AGC CAG CCC GCT GCG-3  and BDNF-
R: 5 -CTC CTG CAC CAA GCC CCA TTC-3  more than
direct sequencing. PCR ampliﬁcation was carried out in a
volume of 25μL containing 100ng DNA; 100μMo fe a c h
dATP, dCTP, dGTP, and dTTP; 1x buﬀer (50mM NaCl,
10mM Tris-HCl, 10mM MgCl2,1 m MD T T ,p H7.5 at
25◦C); 5x of Tuneup solution; 25nM of each primer; 1U of
Taqpolymerase(Nanohelix,SouthKorea).Theampliﬁcation
protocolconditionsselectedwereasfollows:initialdenatura-
tion at 95◦C for 3min, followed by 35 cycles of denaturation
at 94◦C for 30s, annealing at 60◦C for 45s, extension at
72◦Cf o r4 5s ,a n daﬁ n a le x t e n s i o na t7 2 ◦C for 7min. PCR
products were puriﬁed using PureHelix PCR Puriﬁcation










BDNF-T(−)9 7 8 9
∗Two of these patients carry 2 BDNF-T alleles (BDNF T/T) (P = 0.748,
χ2 = 0.10).
Kit according to the manufacturer’s instructions (Nanohelix,
South Korea) and subjected to automatic sequence analysis
(automated sequencer ABI 3130; Applied Biosystems, CA
94404, USA) by BigDye terminator reaction according to
the supplier’s instructions (ABI Prism BigDye Terminator
Cycle Sequencing Ready Reaction Kits Version 3.1; Applied
Biosystems, CA 94404, USA) using BDNF-F: 5 -CAG AGG
AGC CAG CCC GCT GCG-3  primer. The obtained
sequences were analyzed using BioEdit software, version
7.0.5.3 (http://www.mbio.ncsu.edu/bioedit/bioedit.html).
Statisticalanalysiswasperformedbyusingχ2 test.Avalue
of P<0.05 was considered statistically signiﬁcant.
3. Results
PE group consists of 112 children with ages ranging from
2t o1 7y e a r sa n da na v e r a g ea g eo f1 0 . 4( S D :3 . 1 8 )y e a r s ,
those with 85 (75.9%) children in the idiopathic epilepsy
group and 27 (24.1%) children in the symptomatic group.
One hundred control children (51 females, 49 males) with
mean age 10.8 (SD: 3.15) were enrolled in the study.
BDNF 270T allele was found to be in 15 (13%) epileptic
and 11 (11%) control children. The BDNF 270T allele var-
iation was not signiﬁcantly diﬀerent between the two groups
(P = 0.748). Comparison of each group by sex and BDNF
270T allele frequencies is presented in Table 1.
Table 3 shows genotype distribution for the C270T pol-
ymorphism of the BDNF gene among patients with epilepsy
and control group. However, the frequency of genotype
was not signiﬁcantly diﬀerent from that in epilepsy or that
in the controls (P = 0.379). Interestingly, in the epilepsy
group, both two children with TT genotype have post-
traumatic epilepsy. Further, for the genotype frequencies of
BDNF gene polymorphism, all two patient subgroups (idio-
pathic/symptomaticepilepsy),epilepticchildrenwithmental
retardation and cerebral palsy showed similar distribution of
the 270C/T allele (Table 2).
The determination of allelic frequencies of the BDNF
gene for idiopathic and symptomatic epilepsy patients is
presented in Table 3. The most frequent variant is C allele,
in both groups. T allele frequency is higher in the idiopathic
group (11 and 4 children, resp.; P = 0.792). There was
no statisticaly signiﬁcant diﬀerence between the epilepsyThe Scientiﬁc World Journal 3
Table 2: Genotype frequencies of BDNF gene polymorphism in the epilepsy, control, mental retardation, and cerebral palsy subjects.
CC CT TT Total
Control group 89 (89%) 11 (11%) 0 100
Epilepsy group 97 (86.6%) 13 (11.6%) 2 (1.8%)∗ 112
Idiopathic 74 (87%) 10 (11.8%) 1 (1.2%) 85
Symptomatic 23 (85.2%) 3 (11.1%) 1 (3.7%)∗∗ 27
Mental retardation 18 (90) 2 (10%) 0∗∗∗ 20
Cerebral palsy 7 (87.5%) 1 (12.5%) 0∗∗∗∗ 8
∗χ2 = 1.94, P = 0.379, ∗∗χ2 = 0.749, P = 0.688, ∗∗∗χ2 = 1.107, P = 0.575, ∗∗∗∗χ2 = 0.325, P = 0.85.
Table 3: Allele frequencies of BDNF gene polymorphism.
C240T C allele T allele P
Control 189 (94.5%) 11 (5.5%) P = 0.738, χ2 = 0.11
Epilepsy 207 (93.2%) 15 (6.8%)
Idiopathic 158 11 P = 0.792, χ2 = 0.07
Symptomatic 49 4
and control groups for allele frequency of BDNF gene pol-
ymorphism (P = 0.738).
4. Discussion
Various mechanisms and associated genes have been shown
to role in the epileptogenesis, and currently there are many
problems in the treatment of epilepsy a need to new so-
lutions. A genetic contribution to the development of PE as
a sequel of acquired focal brain disorder has been suggested
for a long time. Rimoin and Metrakos [22] concluded that
genetic factors may regulate susceptibility to seizures, not
only by enhancing the vulnerability to epileptiform activity
in some individuals, but also by a protective eﬀect in
others. This genetic predilection, which has been suggested
b u tr e m a i n e du n s p e c i ﬁ e df o rm o r et h a nf o u rd e c a d e s ,i s
now being rapidly elucidated with the recent advances in
gene analysis [23]. With a lifetime incidence of up to 3%,
epilepsy is one of the most common neurological disorders.
Idiopathic epilepsies are assumed to be mainly genetic in
origin,presentwithnormalbrainimaging,andareestimated
to represent up to 47% of all epilepsies [24]. Genetic
alterations can also cause symptomatic epilepsies, as in
cortical malformations.
In our study, we did not ﬁnd any signiﬁcant diﬀerence
between the PE and control groups for the BDNF C270T
variation. To our knowledge, this was the ﬁrst study which
investigates this polymorphism in the childhood epilepsy.
Kanemoto et al. [12] detected an association between the
270T allele polymorphism and partial epilepsy, in a group
of Japanese adult patients. In contrast, Lohoﬀ et al.’s study
[13] failed to document an association between C270T
polimorphisim and temporal lobe epilepsy. It was thought
that this discrepancy for the results has been based on the
ethnic diﬀerences.
In search of a polymorphism in the BDNF gene an
associated study by Kunugi et al. [14] found that the
frequency of the mutated type (T270) was signiﬁcantly
more common in patients with Alzheimer’s disease than in
controls, suggesting a possible association of the T allele
with a low production of BDNF. Nanko et al. [25]d e t e c t e d
signiﬁcantassociationbetweentheTalleleandschizophrenia
in Japanese subjects. Watanabe et al. [26] observed similar
tendency for the T allele frequency although the diﬀerence
was not statistically signiﬁcant. This diverseness may be due
to the diﬀerent ethnicity of the participants or the small
sample sizes.
Various studies have shown that BDNF increased neu-
ronal excitability and is the ability to potentiate glutamater-
gic synaptic transmission. BDNF is highly localized and
upregulated in areas implicated in epileptogenesis. Indeed,
it is perhaps no coincidence that BDNF-immunoreactive
ﬁbersinnervatetheregionsmostvulnerableintemporallobe
epilepsy [27]. BDNF mRNA expression within the central
nervous system has been known to be tightly regulated by
neuronal activity. Seizure activity increases the expression of
BDNF mRNA and protein, and recent studies have shown
that interfering with BDNF signal transduction inhibits the
development of the epileptic state in vivo. Thus, transgenic
mice with decreased BDNF have a higher seizure threshold,
and overexpression of BDNF facilitates seizures [28]. Par-
ticularly interesting is the evidence that BDNF expression
increases after seizures and after other insults as well.
These results contribute to epileptogenesis. This raises the
possibility of designing therapies for this disorder that may
be both anticonvulsant and antiepileptogenic. New evidence
fromhumantissueresectedfromintractableepilepticsshows
that BDNF expression and action in human tissue are
consistent with those in the rat, supporting the hypothesis
that BDNF may play a role in human temporal lobe epilepsy.
Besides, the localization studies have shown in hippocampal
slices from TLE patients that BDNF exposure potentiates
granule cell excitation and impairs granule cell inhibition
[29]. Both the amplitude and frequency of excitatory post-
synaptic currents were increased, and there was a decrease
in amplitude of evoked inhibitory postsynaptic currents.
Subsequentstudies demonstrated additional eﬀectsofBDNF
in hippocampus, such as decreased γ-aminobutyric acid
(GABA)ergic transmission, phosphorilation of N-methyl-d-
aspartate(NMDA)receptors,andactionsatsodiumchannels
[30–32]. These works strongly support a role of BDNF in4 The Scientiﬁc World Journal
human epilepsy and raise the possibility that interference
with BDNF expression or BDNF action may be a therapeutic
strategy for treating epilepsy.
Most of the epilepsy-associated genes identiﬁed so far
encode ion channels. Interestingly, those proteins encoded
by the nonion channel genes have been suggested to interact
with ion channels. This is conceivable from a pathophys-
iological point of view, as ion channels provide the basis
for both the electrophysiological excitability of neuronal cell
membranes and the communication between neurons. Also,
most anticonvulsant drugs in clinical use today modulate
diﬀerent types of ion channels [33]. Genetic techniques have
been developing rapidly. Whole genome approaches now
allow the detection of common genetic variants in complex
genetic syndromes. Chip technology also makes this possi-
ble. The next generation of sequencing techniques is also
developing. This will enable more rapid, more eﬀective, and
cheaper genotyping, so that we expect to ﬁgure out many
more genetic defects in epilepsies and other diseases to be
unravelled in the near future. To translate these ﬁndings
and use them for daily clinical practice is another issue.
However, knowledge of the genetic defects can be relevant
for diagnosis and prognosis and may even have an impact
on therapy, for example, in early use of stiripentol in severe
myoclonicepilepsyofinfancy[34].Theknowledgeofgenetic
defectsandtheirunderlyingmechanismscangiverisetonew
therapeutic strategies in epilepsies in general.
The major hypotheses for the functional eﬀects of insult-
induced neurotrophin changes are protection against neu-
ronal damage and stimulation of sprouting and synaptic
reorganization; therefore, a BDNF gene polymorphism is an
ideal candidate for a genetic predisposition that regulates
development of epileptogenesis following insult to the brain
[35]. The BDNF polymorphism at position 270 lies within
the proBDNF sequence. It may aﬀect the production of
mature and biologically active BDNF by altering proBDNF
processing [36] .L o w e rl e v e l so fm a t u r eB D N Fm a yr e d u c e
the amount of protection of neurons from toxic envi-
ronmental stimuli such as head trauma. Thus, the BDNF
polymorphism at position 270 has the potential to aﬀect the
activity of extracellular proBDNF activity as well, which may
also contribute to development of chronic PE. In our study,
although not statistically signiﬁcant, two patients with PE
haveTTallele,andbothofthemhaveposttraumaticepilepsy.
There was an idiopathic PE dominance, in our patient
population. Some PEs such as Rolandic epilepsy have long
been known to have a strong genetic contribution; however,
t h es t r i c t l ya g e - d e p e n d e n tn a t u r ea sw e l la sf a m i l yh i s t o r y
associated with that condition presents a unique clinical
picture suggestive of a close kinship with idiopathic gen-
eralized epilepsies. Also, many sporadic PE cases cannot
be explained as a single-gene disease, because they seem
as a polygenic or multifactorial. Nevertheless, genetic and
acquired risk factors are frequent in PE patients [12]. In
summary, although we cannot ﬁnd a signicant diﬀerence,
we thought that BDNF gene T allele frequency may enhance
thesusceptibilityofposttraumaticepilepsyandcausechronic
epilepsy in genetically predisposed patients, but further
studies are warranted with a larger sample size.
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